Slides on The Nurse’s Expanding Role in Treating Psoriatic Conditions: Improving Outcomes and Patient Satisfaction

Commentary by Dr. Vinod Chandran on using interleukin inhibitors secukinumab and guselkumab for axial manifestations of psoriatic arthritis, from CCO

Vinod Chandran, MBBS, MD, DM, PhD Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Released: January 11, 2021 Expired: January 10, 2022

Commentary from Dr Jim Treat on counseling parents and children about pros and cons of systemic therapy for pediatric plaque psoriasis, from CCO

Jim Treat, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Released: January 8, 2021 Expired: January 7, 2022

CME for CCO on when to use interleukin inhibitors in psoriatis arthritis: biologic DMARD or MTX naive? IL-17A secukinumab, ixekizumab; IL-12/23 ustekinumab

Vinod Chandran, MBBS, MD, DM, PhD Alexis Ogdie, MD, MSCE Physicians: maximum of 0.5 AMA PRA Category 1 Credits™ Released: December 29, 2020 Expired: December 28, 2021

Guidelines and Therapies

Head-to-Head Studies

CCO slides on when to use interleukins inhibitors in psoriatis arthritis: biologic dmard or MTX naive? IL-17A secukinumab, ixekizumab; IL-12/23 ustekinumab.

Vinod Chandran, MBBS, MD, DM, PhD Alexis Ogdie, MD, MSCE Released: December 29, 2020